Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

British Journal of Dermatology

Volumn 173, Issue 4, 2015, Pages 1024-1031

  Sinha, R ^a,b   Larkin, J ^b   Gore, M ^b   Fearfield, L ^a,b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CORTICOSTEROID; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; CRYOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; ERYTHEMA NODOSUM; FEMALE; FOLLICULITIS; HUMAN; HYPERKERATOSIS; INVESTIGATIVE PROCEDURES; KERATOACANTHOMA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MUTATION; OBSERVATIONAL STUDY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; RARE DISEASE; RETROSPECTIVE STUDY; SCALP PRURITUS; SQUAMOUS CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG ERUPTIONS; GENETICS; MELANOMA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHOTOSENSITIVITY DISORDER; RASH; SKIN NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; INDOLES; KERATOACANTHOMA; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PHOTOSENSITIVITY DISORDERS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; YOUNG ADULT;

EID: 84946235515     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13958     Document Type: Article

References (28)

1. Greaves WO, Verma S, Patel KP, et al,. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013; 15: 220-6.
2. Curtin JA, Fridlyand J, Kageshita T, et al,. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
3. Davies H, Bignell GR, Cox C, et al,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
4. eMC. Zelboraf 240 mg film-coated tablets. Available at: https://www.medicines.org.uk/emc/medicine/26056 (last accessed 5 October 2015).
5. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
6. McArthur GA, Chapman PB, Robert C, et al,. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-32.
7. V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014; 15: 436-44.
8. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html (last accessed 5 October 2015).
9. Adam A, Thomas L, Bories N, et al,. Sarcoidosis associated with vemurafenib. Br J Dermatol 2013; 169: 206-8.
10. Park JJ, Hawryluk EB, Tahan SR, et al,. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol 2014; 150: 307-11.
11. Martinez-Moran C, Najera L, Ruiz-Casado AI, et al,. Interstitial granulomatous drug reaction to sorafenib. Arch Dermatol 2011; 147: 1118-19.
12. Magro CM, Crowson AN, Schapiro BL,. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol 1998; 25: 72-8.
13. Lacouture ME, Duvic M, Hauschild A, et al,. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314-22.
14. Boussemart L, Routier E, Mateus C, et al,. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691-7.
15. Ascierto PA, Minor D, Ribas A, et al,. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31: 3205-11.
16. Hauschild A, Grob JJ, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2012; 380: 358-65.
17. Hatzivassiliou G, Song K, Yen I, et al,. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
18. Heidorn SJ, Milagre C, Whittaker S, et al,. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
19. Poulikakos PI, Zhang C, Bollag G, et al,. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-30.
20. Su F, Viros A, Milagre C, et al,. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
21. Chu EY, Wanat KA, Miller CJ, et al,. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012; 67: 1265-72.
22. Rinderknecht JD, Goldinger SM, Rozati S, et al,. RASopathic skin eruptions during vemurafenib therapy. PLoS ONE 2013; 8: e58721.
23. Flaherty KT, Infante JR, Daud A, et al,. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
24. V600E/K mutation-positive cutaneous melanoma. J Clin Oncol 2014; 32: 5s.
25. Liu HB, Wu Y, Lv TF, et al,. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 2013; 8: e55128.
26. Larson RA, Druker BJ, Guilhot F, et al,. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-8.
27. Rini BI, Cohen DP, Lu DR, et al,. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763-73.
28. Kramkimel N, Sakji L, Thomas-Schoemann A, et al,. Severe skin rash during vemurafenib treatment: a predictive factor of early positive response in metastatic melanoma? J Clin Oncol 2014; 32 (Suppl.): Abstr. 9092.